{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:48:22Z","timestamp":1792792102224,"version":"4.5.0"},"reference-count":114,"publisher":"Baishideng Publishing Group Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4254\/wjh.v9.i5.227","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T20:49:05Z","timestamp":1487278145000},"page":"227","source":"Crossref","is-referenced-by-count":67,"title":["Adverse effects of oral antiviral therapy in chronic hepatitis B"],"prefix":"10.4254","volume":"9","author":[{"given":"Bircan","family":"Kayaaslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmet","family":"Guner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.04.004"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr388"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-3357.","DOI":"10.1128\/JVI.69.6.3350-3357.1995"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12499"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-8-281"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1586\/egh.12.52"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22885"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Wolters LM, Niesters HG, de Man RA. Nucleoside analogues for chronic hepatitis B. Eur J Gastroenterol Hepatol 2001;13:1499-1506.","DOI":"10.1097\/00042737-200112000-00016"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.021"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-2749.","DOI":"10.1128\/AAC.38.12.2743"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.06.011"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.019"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.006"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1139573"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2013-202069"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-012-9633-3"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-010-9238-7"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24118"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Palumbo E. Lamivudine for chronic hepatitis B: a brief review. Braz J Infect Dis 2008;12:355-357.","DOI":"10.1590\/S1413-86702008000500002"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002;17:409-414.","DOI":"10.1046\/j.1440-1746.2002.02767.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1532.","DOI":"10.1053\/jhep.2001.25084"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.026"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722.","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, Graziadei I, Encke J, Schmidt H, Vogel W. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256-263.","DOI":"10.1111\/j.1365-2893.2005.00695.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02396.x"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13187"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12598"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.","DOI":"10.7326\/0003-4819-148-7-200804010-00008"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Liberek A, Szaflarska-Pop\u0142awska A, Korzon M, \u0141uczak G, G&oacute;ra-Gebka M, \u0141o\u015b-Rycharska E, Bako W, Czerwionka-Szaflarska M. Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006;12:2412-2416.","DOI":"10.3748\/wjg.v12.i15.2412"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.14661\/2014.863-86"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Yahagi K, Ueno Y, Mano Y, Shimosegawa T. Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis. Liver Transpl 2002;8:1198-1199.","DOI":"10.1053\/jlts.2002.36734"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Holt SG, Moore KP. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med 2001;27:803-811.","DOI":"10.1007\/s001340100878"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Adani GL, Baccarani U, Risaliti A, Bresadola F, Della Rocca G, Viale P. Rhabdomyolysis due to Lamivudine administration in a liver transplant recipient. Am J Transplant 2005;5:634.","DOI":"10.1111\/j.1600-6143.2005.00691.x"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Song X, Hu Z, Zhang H. Acute dystonia induced by lamivudine. Clin Neuropharmacol 2005;28:193-194.","DOI":"10.1097\/01.wnf.0000172367.71932.61"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Kaptanoglu AF, Kutluay L. Ichthyosiform eruption associated with lamivudine in a patient with chronic hepatitis-B infection. Int J Clin Pract 2005;59:1237-1238.","DOI":"10.1111\/j.1368-5031.2005.00618.x"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Tuon FF, Guastini CM, Boulos MI. Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis. Braz J Infect Dis 2008;12:263.","DOI":"10.1590\/S1413-86702008000400001"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Soylu AR, D&ouml;kmeci G, Tezel A, Cakir B, Umit H, Karahan N, Amuca H. Lamivudine-induced acute pancreatitis in a patient with decompensated Hbv-related chronic liver disease. J Clin Gastroenterol 2004;38:134.","DOI":"10.1097\/00004836-200402000-00010"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.032"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12173"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01412.x"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Zhang XS, Jin R, Zhang SB, Tao ML. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 2008;14:3549-3553.","DOI":"10.3748\/wjg.14.3549"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i33.5575"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536.","DOI":"10.1016\/j.gastro.2005.05.053"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.","DOI":"10.1056\/NEJMoa020681"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003;63:2215-2234.","DOI":"10.2165\/00003495-200363200-00007"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007313325"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.","DOI":"10.1056\/NEJMoa021812"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23346"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13046"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther 2006;28:184-203.","DOI":"10.1016\/j.clinthera.2006.02.012"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12467"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05455.x"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28015"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i23.7169"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.7727\/wimj.2013.198"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008;52:598-605.","DOI":"10.1128\/AAC.01122-07"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.10.024"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.7862"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i43.6290"},{"key":"ref61","unstructured":"Bristol-Myers Squibb. Baraclude&reg; (entecavir): US prescribing information [online]. [Accessed 2016 Sept 16]. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/packageinserts.bms.com\/pi\/pi_baraclude.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/packageinserts.bms.com\/pi\/pi_baraclude.pdf<\/ext-link>."},{"key":"ref62","unstructured":"Gilead Sciences, Inc. Viread&reg; (tenofovir disoproxil fumarate) tablets: US prescribing information [online]. [Accessed 2016 Sept 16]. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021356s035lbl.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021356s035lbl.pdf<\/ext-link>."},{"key":"ref63","unstructured":"Novartis. Tyzeka (telbivudine): US prescribing information [online]. [Accessed 2016 Sept 16]. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tyzeka.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tyzeka.pdf<\/ext-link>."},{"key":"ref64","unstructured":"Gilead Sciences, Inc. Hepsera (adefovir dipivoxil) tablets: US prescribing information [online]. [Accessed 2016 Sept 16]. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021449s016lbl.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021449s016lbl.pdf<\/ext-link>."},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2011.06.013"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2165\/11208510-000000000-00000"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9080-3"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.653340"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13377"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Marcellin P, Zoulim F, H&eacute;zode C, Causse X, Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. Dig Dis Sci 2016;61:3072-3083.","DOI":"10.1007\/s10620-015-4027-8"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu471"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31819c20d8"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835192ae"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.011"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27894"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3486-7"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.028"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.672972"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002400"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.03.030"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Yang Q, Shi YU, Yang Y, Lou G, Lv F. Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis. Biomed Rep 2015;3:269-275.","DOI":"10.3892\/br.2015.415"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Eguchi H, Tsuruta M, Tani J, Kuwahara R, Hiromatsu Y. Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. Intern Med 2014;53:233-237.","DOI":"10.2169\/internalmedicine.53.1213"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-1803.","DOI":"10.1111\/j.1572-0241.2006.00647.x"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, Brosgart CL, Westland C, Arterbrun S, Deray G; Adefovir Dipivoxil International 437 Study Group; Adefovir Dipivoxil International 438 Study Group. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:1153-1158.","DOI":"10.1111\/j.1523-1755.2004.00866.x"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181e12ed3"},{"key":"ref87","unstructured":"Samarkos M, Theofanis V, Eliadi I, Vlachogiannakos J, Polyzos A. Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B. J Gastrointestin Liver Dis 2014;23:342."},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2954"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.09.016"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2649"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.remn.2013.05.011"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-1073.","DOI":"10.1086\/368314"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01602.x"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.04.008"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-015-0193-1"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23788"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182100f59"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12220"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i2.189"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13036"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12108"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.09.031"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.962604"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12538"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Wong F, Pai R, Van Schalkwyk J, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Ann Hepatol 2014;13:187-195.","DOI":"10.1016\/S1665-2681(19)30881-6"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.02.003"},{"key":"ref107","unstructured":"FDA Pregnancy Categories. [Updated Mar 30th, 2016]. [Access date: Apr 24th, 2016]. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.drugs.com\/pregnancy-categories.html\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.drugs.com\/pregnancy-categories.html<\/ext-link>."},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Yu M, Jiang Q, Ji Y, Jiang H, Wu K, Ju L, Tang X, Wu M. The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus. Eur J Clin Microbiol Infect Dis 2012;31:2211-2218.","DOI":"10.1007\/s10096-012-1557-2"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01056.x"},{"key":"ref110","unstructured":"Antiretroviral Pregnancy Registry [Internet]. WHO. [Updated 2015 Dec 17]. [Access date: 20.03.2016]. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.apregistry.com\/InterimReport.aspx\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.apregistry.com\/InterimReport.aspx<\/ext-link>."},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i48.9377"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.038"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i8.2504"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-08"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v9\/i5\/227.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T11:49:29Z","timestamp":1601639369000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v9\/i5\/227.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v9.i5.227","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}